Posted by This talk is the second in a series of healthcare-related talks the Board of Directors of our Fairfield Columbia Alumni Association brings to you.
Attend to hear a talk on COVID-19 given by an expert scientist, Yale University Associate Professor, Dr. Onyema Ogbuagu, who is Yale's principal investigator on multiple investigational therapeutic and preventative clinical trials for COVID-19. The trials he has conducted include remdesivir (now FDA approved), leronlimab and remdesivir and tocilizumab combination therapy as well as the Pfizer/BioNTech Vaccine trial.
| To register, please provide information and click "SEND RSVP." You will receive an RSVP confirmation email with a link to click to complete a form and receive the Zoom meeting login details. |
The talk will discuss:
- Challenges with conducting COVID-19 trials
- How treatments and vaccines are evaluated for safety and efficacy
- Current vaccine technologies and their promise for future infectious diseases outbreaks or existing diseases
The talk ends in a moderated Q&A to answer your questions. Register now to secure your place.
Dr. Onyema Ogbuagu, Brief Bio
Onyema Ogubagu, MBBCh, FACP, FIDSA, is a member of the Yale AIDS Clinical Trials Program, and Director of the Program (since May 2017) and have been a principal and or co-investigator on numerous pharmacokinetic, phase 2 and 3 safety and efficacy trials of novel antiviral compounds (HIV).
He also provides care for COVID-19 patients and leads Yale’s clinical studies around COVID-19.
One of a doctor’s most important roles is to reassure patients, Dr. Ogbuagu says, and information often helps. “For HIV, we are able to tell people now that treatments have evolved to the point where most people with the virus have a normal life expectancy—all you need to do is take your medicine to keep the virus at bay. For COVID, I remind patients that the majority of people have good outcomes, even among the elderly, so that is in their favor.” He adds that patients at Yale who enroll in clinical trials have the advantage of access to potentially effective therapies before they are FDA-approved.
In addition to his work at Yale, Dr. Ogbuagu contributes to creating sustainable patient care, supporting training, and furthering research activities and patient services in Liberia and Rwanda. “I’ve trained a whole generation of physicians in Rwanda, and the first infectious disease fellow ever in Liberia. I think we are making some steps in the right direction,” he says.
Selected Publications:
|
A new positive SARS-CoV-2 test months after severe COVID-19 illness: reinfection or intermittent viral shedding? Tuan J, Spichler-Moffarah A, Ogbuagu O. A new positive SARS-CoV-2 test months after severe COVID-19 illness: reinfection or intermittent viral shedding? BMJ Case Reports 2021, 14.
|
|
Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine. Polack FP, Thomas SJ, Kitchin N, Absalon J, Gurtman A, Lockhart S, Perez JL, Pérez Marc G, Moreira ED, Zerbini C, Bailey R, Swanson KA, Roychoudhury S, Koury K, Li P, Kalina WV, Cooper D, Frenck RW Jr, Hammitt LL, Türeci Ö, Nell H, Schaefer A, Ünal S, Tresnan DB, Mather S, Dormitzer PR, Şahin U, Jansen KU, Gruber WC, C4591001 Clinical Trial Group.. Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine. N Engl J Med 2020, 383:2603-2615.
|
|
Effect of Remdesivir vs Standard Care on Clinical Status at 11 Days in Patients With Moderate COVID-19: A Randomized Clinical Trial. Spinner CD, Gottlieb RL, Criner GJ, Arribas López JR, Cattelan AM, Soriano Viladomiu A, Ogbuagu O, Malhotra P, Mullane KM, Castagna A, Chai LYA, Roestenberg M, Tsang OTY, Bernasconi E, Le Turnier P, Chang SC, SenGupta D, Hyland RH, Osinusi AO, Cao H, Blair C, Wang H, Gaggar A, Brainard DM, McPhail MJ, Bhagani S, Ahn MY, Sanyal AJ, Huhn G, Marty FM. Effect of Remdesivir vs Standard Care on Clinical Status at 11 Days in Patients With Moderate COVID-19: A Randomized Clinical Trial. JAMA 2020, 324:1048-1057.
|
|
Transmission risk of respiratory viruses in natural and mechanical ventilation environments: implications for SARS-CoV-2 transmission in Africa. Sopeyin A, Hornsey E, Okwor T, Alimi Y, Raji T, Mohammed A, Moges H, Onwuekwe EVC, Minja FJ, Gon G, Ogbuagu O, Ogunsola F, Paintsil E. Transmission risk of respiratory viruses in natural and mechanical ventilation environments: implications for SARS-CoV-2 transmission in Africa. BMJ Global Health 2020, 5.
|